ABUS (Arbutus Biopharma) 6-Month Price Index: 1.09 (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABUS Arbutus Biopharma Corp ABUS
53 GF Score
Price $5.07
GF Value $49.41
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Arbutus Biopharma 6-Month Price Index?

Arbutus Biopharma ABUS -1.93% 53 6-Month Price Index is 1.09 as of Aug. 29, 2026. GuruFocus rates ABUS with a GF Score™ of 53/100 and a GF Value™ of $49.41 (Possible Value Trap). The stock has 4 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-29), Arbutus Biopharma's 6-Month Price Index is 1.09.

Arbutus Biopharma  (NAS:ABUS) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Arbutus Biopharma 6-Month Price Index Related Terms

ABUS vs TBPH, ANNX, SANA: 6-Month Price Index Comparison

For the Biotechnology subindustry, Arbutus Biopharma's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABUS
53GF Score
Arbutus Biopharma Corp ABUS
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma  (NAS:ABUS) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.09 mean?
Arbutus Biopharma (ABUS) has a 6-Month Price Index of 1.09 as of Aug. 29, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's 6-Month Price Index too high?
Arbutus Biopharma's current 6-Month Price Index is 1.09. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's 6-Month Price Index compare to TBPH and ANNX?
Arbutus Biopharma's 6-Month Price Index of 1.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current 6-Month Price Index is 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $49.41, compared to a current price of $5.07 — trading 89.7% below its estimated fair value. The current 6-Month Price Index is 1.09. Arbutus Biopharma's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current 6-Month Price Index is 1.09 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $5.07 is trading 89.7% below its estimated GF Value™ of $49.41. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • 6-Month Price Index: 1.09
  • GF Value™: $49.41 vs. price of $5.07 (89.7% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for ABUS

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.07
Price
$49.41
GF Value